The majority of clinical trial delays and budget overruns do not originate from a single catastrophic failure. They accumulate – a site activation that takes six weeks longer than planned, a monitoring finding that was not escalated until the next visit, a data query backlog that grew unnoticed because data management and monitoring were not communicating, a regulatory response that was handled slowly because the submission team did not have visibility into study conduct.
These are coordination failures, and they are endemic in outsourced clinical development models where functions are managed in silos – monitoring vendor, data vendor, safety vendor, regulatory consultant – each accountable for their own output but not for the integrated result.
At APICES, project management and clinical operations sit at the centre of a fully integrated delivery model. The project manager does not manage vendors. The project manager manages the study – with direct authority over monitoring, data management, safety, regulatory, and medical writing functions that are all in-house.
Each study at APICES is run by a senior project manager who owns delivery from kick-off to close-out. There is no account management layer, no programme director who translates between the sponsor and the operational team, and no escalation path that passes through multiple organisational levels before a decision is made. Sponsors have direct access to the PM and to the senior functional leads.
Operational planning is built from the study's specific characteristics: protocol complexity, country mix, site profile, regulatory submission sequence, and data management requirements. Plans are not templates adjusted to fit the study; they are built around the study. Timeline commitments are reviewed against operational reality – country-specific start-up lead times, ethics committee behaviour, site activation requirements – not against generic industry benchmarks.
Multi-country studies are coordinated through country-specific operational leads who own regulatory submissions, site relationships, and monitoring in their geography, reporting into the central PM on shared milestones.
The integration between project management and clinical functions at APICES has measurable operational consequences. Monitoring findings are reviewed in the same operational meeting where data management queries are discussed. Safety events are communicated to the PM the same day they are reported, not in a weekly safety report. Regulatory milestone slippage triggers an operational response, not just a timeline update.
For CRO rescue engagements – studies that are missing milestones, have experienced team turnover, or have accumulated compliance risk – this integrated structure enables a rapid reset. APICES has taken over multinational Phase III oncology programmes in progress. The capability exists not because of a rescue protocol, but because the operational structure can absorb a study quickly and establish control without relying on the outgoing vendor's documentation.
Sponsors at APICES receive weekly written status updates covering milestone progress, open risks, data management performance, and upcoming decisions. Monthly governance reviews address study trajectory, budget performance, and strategic decisions. Escalation occurs immediately when scope, timeline, or assumptions require a sponsor decision – not at the next scheduled meeting.
System access is provided transparently: sponsors can access the CTMS, eTMF, and EDC system at read-level at any time. We work in sponsor-preferred systems where required; otherwise we run on validated APICES platforms and provide full access for oversight.
Who runs APICES studies day-to-day?
A senior project manager owns delivery from kick-off to close-out. Sponsors have direct access to the PM and the senior leads, with no account-management layer in between.
How does APICES handle multi-country coordination?
A central PM coordinates country-specific leads. Country leads own regulatory, contracts, monitoring, and site relationships in their geography while reporting to the central PM on shared milestones.
What is your sponsor reporting cadence?
Default is weekly written status with monthly governance review, plus immediate escalation when scope, timeline, or assumptions need a sponsor decision. Cadence is adjusted to the programme.
Can you take over a study mid-flight?
Yes. We perform CRO rescue takeovers for trials that are missing milestones, have lost institutional knowledge, or need a senior reset. We have done this on multinational Phase III oncology programmes.
Do you use sponsor systems or APICES systems?
Either. We work in sponsor-preferred CTMS, EDC, and eTMF where required; otherwise we run on validated APICES systems and provide read access for transparency.
If you are preparing your next early clinical study or want to sanity-check how your program is set up, the next step is a focused conversation.
No packaged answers. Just context, experience, and a clear view on fit.
